麻豆AV

闭じる

消化器外科スタッフ(旧原医研外科)

浜井　洋一　（ HAMAI　Yoichi ）
浜井　洋一

役职：诊疗准教授
専门分野：消化器外科
资格
?日本外科学会外科専门医?指导医
?日本消化器外科学会消化器外科専门医?指导医
论文?出版物：

伊富貴　雄太　（ IBUKI　Yuta ）
伊富貴　雄太

役职：助教
専门分野：消化器外科
资格
?日本外科学会外科専门医
?日本消化器外科学会消化器外科専门医
?日本临床肿疡学会がん薬物疗法専门医
论文?出版物：

廣畑　良輔　（ HIROHATA　Ryosuke ）
廣畑　良輔

役职：医科诊疗医
専门分野：消化器外科
资格
?日本外科学会外科専门医
?日本消化器外科学会消化器外科専门医

大澤　真那人　（ OHSAWA　Manato ）

役职：医科诊疗医
専门分野：消化器外科
资格
?日本外科学会外科専门医
?日本消化器外科学会消化器外科専门医
论文?出版物：

  1. Impact of Fusobacterium nucleatum in the treatment of cancer, including radiotherapy and its future potential in esophageal cancer. J Radiat Res. 2024 Dec 16;65(Supplement_1):i126-i134.
  2. Recurrence and prognostic predictors in pathologic T1N0 esophageal squamous cell carcinoma treated with surgery alone.Surgery. 2024 Oct 16:S0039-6060(24)00786-4.
  3. Association between prognosis and lymph node status using 18F-fluorodeoxyglucose-positron emission tomography in esophageal squamous cell carcinoma treated with esophagectomy post-neoadjuvant chemotherapy.World J Surg. 2024 Mar;48(3):650-661.
  4. Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma. Front Oncol. 2023 Apr 17;13:1126536.
  5. The treatment efficacy and prognosis of each treatment in early postoperative recurrence of esophageal squamous cell carcinoma. Surg Today. 2023 May 25.
  6. Blood biomarkers as predictors of pathological lymph node metastasis in clinical stage T1N0 esophageal squamous cell carcinoma. Dis Esophagus. 2022 Jul 3:doac042.
  7. Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma. Anticancer Res. 2022 Mar;42(3):1499-1507.
  8. Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy. Surgery. 2022 Aug;172(2):584-592.
  9. Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma. World J Surg. 2022 Aug;46(8):1934-1943.
  10. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. Anticancer Res. 2022 Dec;42(12):6037-6045.
  11. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. In Vivo. 2022 Nov-Dec;36(6):2852-2860.
  12. Recurrent esophageal adenocarcinoma derived from ectopic gastric mucosa: A case report. Thorac Cancer. 2022 Mar;13(6):876-879.
  13. Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma. Anticancer Res. 2022 May;42(5):2791-2795.
  14. Prospective Randomized Trial of Early Postoperative Enteral and Total Parenteral Nutrition for Treating Esophageal Cancer. Anticancer Res. 2021 Dec;41(12):6237-6246.
  15. Distribution of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma After Trimodal Therapy. Ann Surg Oncol. 2021 Mar;28(3):1798-1807.
  16. Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy. Anticancer Res. 2021 Jun;41(6):3011-3021.
  17. Prediction of the tumor response and survival based on computed tomography in esophageal squamous cell carcinoma after trimodality therapy. Surg Today. 2021 Apr 2.
  18. Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy. Ann Surg Oncol. 2020 Oct;27(11):4422-4430.
  19. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy. Anticancer Res. 2020 Aug;40(8):4387-4394.
  20. 腹膜播種による腸閉塞に対する緩和手術成績と予後因子Outcomes and Prognostic Factors in Patients who Underwent Palliative Surgery for Malignant Bowel Obstruction due to Peritoneal Dissemination 日本臨床外科学会雑誌 81(6), 1029-1035, 2020
  21. Successful management of esophageal cancer with perforation using bypass surgery followed by definitive chemoradiotherapy. in vivo. 2020;34: 2169-2172
  22. Rare pancreatic metastasis of undifferentiated pleomorphic sarcoma originating from the pelvis: A case report. Int J Surg Case Rep. 2020;68:140-144.
  23. Thoracoscopic double-flap reconstruction for esophagogastric junction cancer: A case report. Int J Surg Case Rep. 2020;67:102-105.
  24. Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery. Anticancer Res. 2020 Feb;40(2):1153-1160.
  25. Rare squamous cell carcinoma arising from a presacral epidermoid cyst: A case report. Int J Surg Case Rep. 2020;66:283-287.
  26. Predicting Severe Postoperative Complication in Patients With Lung Cancer and Interstitial Pneumonia. Ann Thorac Surg. 2020 Apr;109(4):1054-1060.
  27. Long-term Esophageal Cancer Survivor Treated by Bypass for Esophagobronchial Fistula After Chemoradiotherapy: A Case Report. Anticancer Res. 2019 Aug;39(8):4399-4403.
  28. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma. Anticancer Res. 2019 Mar;39(3):1433-1440.
  29. Laparoscopic excision of a retroperitoneal schwannoma: A case report. Asian J Endosc Surg. 2019 Apr;12(2):192-196.
  30. A rare case of retroperitoneal hemolymphangioma. Int J Surg Case Rep. 2018;51:107-111.
  31. 腹腔鏡下に切除した大網原発脂肪腫捻転の1例. 広島医学 (Journal of the Hiroshima Medical Association) 71(3), 202-205, 2018
  32. Abdominoperineal Resection for Anal Metastasis of Rectal Cancer. Gan To Kagaku Ryoho. 2017 Nov;44(12):1364-1366.

北﨑　直　（ KITASAKI　Nao ）
北﨑　直

役职：医科诊疗医
専门分野：消化器外科

(2025年4月更新)

← 外来担当医师ページへ戻る


up

広岛大学病院

〒734-8551　広岛市南区霞1-2-3
TEL:082-257-5555 (代表)